EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Progress in Nanocarriers‐Based Approaches for the Delivery of Tyrosine Kinase Inhibitors in Bone Cancer: Trends and Prospects

Dexin Xu, Wenbin Zhang, Yinping Pan, Wenhai Wang, Dongna Wang, Jian Ding iD

IUBMB Life · 2025-08 · 77 (8)

DOI: 10.1002/iub.70052 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift IUBMB Life, online erschienen am 20.08.2025. Verfasst von Dexin Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Jilin Province FAW General Hospital, Changchun, China. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Bone Neoplasms, Nanoparticles, Drug Carriers. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 131 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bone cancer remains a life‐threatening malignancy predominantly affecting pediatric and adolescent populations, with tyrosine kinase inhibitors (TKIs) emerging as promising therapeutic agents; however, their clinical utility is limited by poor bioavailability, systemic toxicity, and inadequate tumor targeting. Recent advancements in nanocarrier‐based delivery systems have significantly mitigated these limitations by enhancing targeted accumulation of TKIs at tumor sites, reducing off‐target effects, and enabling controlled drug release. Various nanocarrier platforms, including liposomes, polymeric nanoparticles, micelles, dendrimers, metal‐ and metal oxide‐based nanoparticles, carbon‐based carriers, polymeric implants, and hydroxyapatite‐based systems, have been systematically evaluated for their efficacy in delivering TKIs for bone cancer therapy. This review further examines the impact of nanoparticle size on cellular uptake and tumor penetration, with emphasis on liposomal and proteinaceous carriers (albumin‐bound and transferrin‐conjugated nanoparticles) that optimize tumor selectivity while minimizing systemic toxicity. Inorganic nanocarriers such as gold, silver, and metal oxides also demonstrate potential for multimodal therapeutic and diagnostic applications. Notwithstanding these advances, challenges including drug resistance, toxicity, and regulatory barriers remain, necessitating ongoing efforts to optimize nanocarrier formulations. This comprehensive review provides critical insights into the evolving landscape of nanotechnology‐driven TKI delivery strategies aimed at enhancing therapeutic outcomes in bone cancer management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsBone NeoplasmsNanoparticlesDrug CarriersAntineoplastic AgentsDrug Delivery SystemsHumansAnimalsLiposomesTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

liposomes polymeric nanoparticlesmicelles dendrimers metal‐based Nano carriersnanotechnologytyrosine kinase inhibitors (TKI) Nano carriers

Substanzen

Protein Kinase InhibitorsDrug CarriersAntineoplastic AgentsLiposomesTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Orthopedics, Jilin Province FAW General Hospital, Changchun, China.
  • Department of Cardiology, Jilin Province FAW General Hospital, Changchun, China.
  • Department of Pediatrics, Jilin Province FAW General Hospital, Changchun, China.
  • Department of Anesthesiology, Jilin Province FAW General Hospital, Changchun, China.
  • Department of Electrodiagnosis, Jilin Province FAW General Hospital, Changchun, China.

ORCID-Profile: Jian Ding

Zitieren

APA

Xu, D., Zhang, W., Pan, Y., Wang, W., Wang, D., & Ding, J. (2025). Progress in Nanocarriers‐Based Approaches for the Delivery of Tyrosine Kinase Inhibitors in Bone Cancer: Trends and Prospects. IUBMB Life, 77(8). https://doi.org/10.1002/iub.70052

Vancouver

Xu D, Zhang W, Pan Y, Wang W, Wang D, Ding J. Progress in Nanocarriers‐Based Approaches for the Delivery of Tyrosine Kinase Inhibitors in Bone Cancer: Trends and Prospects. IUBMB Life. 2025;77(8). doi:10.1002/iub.70052

BibTeX
@article{Xu2025,
  author = {Xu, Dexin and Zhang, Wenbin and Pan, Yinping and Wang, Wenhai and Wang, Dongna and Ding, Jian},
  title = {Progress in Nanocarriers‐Based Approaches for the Delivery of Tyrosine Kinase Inhibitors in Bone Cancer: Trends and Prospects},
  journal = {IUBMB Life},
  year = {2025},
  volume = {77},
  number = {8},
  doi = {10.1002/iub.70052}
}
Kostenlos starten →